Speaker: 

Jeremiah Jacobs, Pharm.D., Acute Care Clinical Pharmacist, Geisinger Medical Center - has nothing to disclose.

Moderator: 

Sarah F. Hale, Pharm.D., BCPPS; Director of Pharmacy, Geisinger Medical Center - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Explain the use of methylene blue or hydroxocobalamin in the treatment of vasoplegic shock.
• Identify the importance of identifying novel second line therapies for the treatment of vasoplegic shock.
• Describe the rationale for administering alteplase for the treatment of acute pulmonary embolism (PE).
• Provide the benefits and risks of reducing the alteplase dose in the treatment of acute PE.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD; Brain Simpkins, PharmD; Jessica Milheim, CPhT and Nichole Varela Gonzalez, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.